February 2018

　　The international medical journal Human Gene Therapy published a 12-year clinical review of gene therapy, summarizing the safety and effectiveness of clinical treatment of "recombinant human p53 adenovirus injection" since its launch.

　　Clinicians have used "recombinant human p53 adenovirus injection" to treat more than 100，000 patients with malignant tumors from more than 50 countries around the world;

　　The total clinical efficacy (CR+PR) is as high as 90%-96%;